Associated Papers
Impact of genetic variations on the pharmacokinetics, dose requirements, and clinical effects of propofol: a systematic review.
Gerstman MD et al.
British Journal of Anaesthesia, 2025
CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project.
Gaedigk A et al.
The Journal of Molecular Diagnostics : Jmd, 2022
Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population.
Wang D et al.
Frontiers in Cardiovascular Medicine, 2022
Sulfamethoxazole-trimethoprim-induced liver injury and genetic polymorphisms of NAT2 and CYP2C9 in Taiwan.
Huang YS et al.
Pharmacogenetics and Genomics, 2021
PharmVar GeneFocus: CYP2C9.
Sangkuhl K et al.
Clinical Pharmacology and Therapeutics, 2021
Low-frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation.
Claudio-Campos K et al.
Pharmacogenomics, 2019
CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements.
Claudio-Campos KI et al.
Pharmacogenomics, 2019
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
Daly AK et al.
Journal of Personalized Medicine, 2017
Longrange PCR-based next-generation sequencing in pharmacokinetics and pharmacodynamics study of propofol among patients under general anaesthesia.
Zakerska-Banaszak O et al.
Scientific Reports, 2017
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.
Duconge J et al.
Plos One, 2016
Pharmacogenetics of healthy volunteers in Puerto Rico.
Claudio-Campos K et al.
Drug Metabolism and Personalized Therapy, 2015
Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromarone.
Roberts RL et al.
Joint Bone Spine, 2014
Molecular genetic mechanisms of chronic urticaria.
Losol P et al.
Allergy, Asthma & Immunology Research, 2014
CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects.
Cavallari LH et al.
Pharmacogenetics and Genomics, 2013
Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2.
Si D et al.
Biopharmaceutics & Drug Disposition, 2012
CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.
Wang D et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2012
Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria.
Palikhe NS et al.
Allergy, Asthma & Immunology Research, 2011
Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF et al.
Toxicology, 2010
A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.
Lee SJ et al.
British Journal of Clinical Pharmacology, 2010
CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
Chaudhry AS et al.
The Journal of Pharmacology and Experimental Therapeutics, 2010
Novel CYP2C9 promoter variants and assessment of their impact on gene expression.
Kramer MA et al.
Molecular Pharmacology, 2008
CYP450 pharmacogenetics for personalizing cancer therapy.
van Schaik RH
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2008
Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese.
Maekawa K et al.
Pharmacogenetics and Genomics, 2006
Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians.
DeLozier TC et al.
The Journal of Pharmacology and Experimental Therapeutics, 2005
Discovery of new potentially defective alleles of human CYP2C9.
Blaisdell J et al.
Pharmacogenetics, 2004
The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.
Sandberg M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2004